Oscar Health Earnings Call Signals Profitable Scale

Oscar Health, Inc. ((OSCR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Oscar Health, Inc. struck an upbeat tone on its latest earnings call, underscoring powerful top-line momentum, record membership and a sharp turn in profitability. Management balanced that optimism with caution around elevated early-year risk adjustment, seasonal claim patterns and reserve variability, but reiterated confidence by reaffirming full-year guidance and pointing to improving visibility after midyear data.

Explosive Revenue Growth Fuels Top-Line Momentum

Oscar reported first-quarter 2026 revenue of $4.6 billion, up 53% year over year as higher membership and rate increases flowed through the income statement. Management framed this surge as evidence that the company is gaining share in the individual market while improving pricing discipline rather than simply chasing volume.

Record Membership Underscores Market Share Gains

Membership ended Q1 at about 3.2 million, a 56% jump versus last year, and the company began Q2 with roughly 3.0 million paid members. Growth was driven by above-market performance during open enrollment and solid retention, reinforcing Oscar’s positioning as a scaled, national player in individual and small-group coverage.

Profitability Surges to Best Levels in Company History

Earnings from operations hit $704 million in Q1, nearly two and a half times higher than a year ago and up $407 million. Net income reached about $679 million, or $2.07 per diluted share, and adjusted EBITDA climbed to $727 million, all described as the strongest results in the company’s history.

Loss Ratios and Margins Move in the Right Direction

The medical loss ratio improved 490 basis points year over year to 70.5% in the quarter, reflecting better pricing, utilization management and risk capture. Operating margin expanded to 15.2%, up 540 basis points, showing that Oscar is converting scale and operational efficiencies into sustainable profitability.

SG&A Discipline Delivers Operating Leverage

The SG&A ratio fell to 15.2%, a 60-basis-point improvement and the lowest level the company has reported. While SG&A dollars rose 46% year over year, they grew more slowly than revenue, highlighting operating leverage as Oscar spreads fixed costs over a larger premium base.

Balance Sheet Strength Supports Growth Ambitions

Oscar closed the quarter with roughly $8.1 billion in cash and investments, including $279 million at the parent company. Its insurance subsidiaries held approximately $1.7 billion of capital and surplus, with about $809 million considered excess, giving management flexibility to weather volatility and fund growth initiatives.

Tech, AI and New Channels Extend the Growth Runway

Management spotlighted new transparency tools such as real-time drug pricing and scaled AI-driven, bilingual voice agents aimed at improving member experience and efficiency. The launch of the ICHRA X data exchange and Lucie Health Marketplace, a carrier-agnostic platform, is expected to contribute modestly in 2026 but is seen as a meaningful long-term growth driver.

Elevated Risk Adjustment Weighs on Early-Year Metrics

Risk adjustment payable in the first quarter ran around the mid-20% range of direct premiums, above Oscar’s full-year expectation of roughly 20%. Executives emphasized that this timing effect, combined with seasonally low claims, temporarily suppresses recognized revenue and some profitability metrics, and they expect normalization over the year.

Seasonal Claims Patterns Cloud Early Morbidity Readings

First-quarter claims came in seasonally light, making it harder to gauge true morbidity and how it compares with pricing assumptions. Management said early signals suggest market risk is in line with or better than expectations, but they are waiting on second-quarter claims development and external analyses to firm up their view.

Reserve Development Shows State-Level Volatility

Prior-period development was a net favorable $68 million, driven by roughly $150 million of favorable claims runout partially offset by about $85 million of adverse development in certain states. Executives pointed to this mix as evidence that while overall reserves are adequate, there is meaningful volatility in state-by-state performance that they continue to refine.

Membership Churn Normalizing After Exceptional Growth

Membership declined from 3.4 million at year-end to 3.2 million at the end of Q1, and about 3.0 million members were paid as of April 1. Management noted that roughly 200,000 enrollees never made a payment and that they expect gradual churn through the year as enrollment trends revert toward pre-pandemic policy levels.

Seasonality Shapes Interpretation of Yearly Guidance

Despite strong Q1 results, Oscar reiterated its full-year MLR target of 82.4% to 83.4%, signaling that medical costs will run higher later in the year. The CFO also cautioned that Q1 SG&A is likely the annual low point and that the SG&A ratio could move sideways or slightly higher as open enrollment and other seasonal costs ramp.

Execution Risks Remain Amid a Shifting Market

Management highlighted weekly enrollment and morbidity trends and evolving risk adjustment figures as key swing factors for 2026 EBITDA. They also flagged uncertainty around how market contraction, a shift toward bronze plans and ultimate claims experience will settle over the full year, even as current data remain encouraging.

Guidance Reinforced by Strong Start but Tempered by Seasonality

Oscar reaffirmed 2026 guidance for revenue between $18.7 billion and $19.0 billion, an MLR of 82.4% to 83.4%, an SG&A ratio of 15.8% to 16.3% and earnings from operations of $250 million to $450 million, with adjusted EBITDA roughly $115 million higher. That outlook leans on a robust first quarter and a strong balance sheet, while assuming risk adjustment moves back toward 20% of premiums and churn gradually normalizes.

Oscar’s latest earnings call painted the picture of a company that has turned the corner from growth-at-any-cost to profitable scaling, with record membership and strong margins. For investors, the key watchpoints now are how risk adjustment, churn and claims seasonality play out against guidance, but management’s reaffirmed outlook suggests confidence that the early momentum is durable.